New Age Alpha Advisors LLC Takes $221,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

New Age Alpha Advisors LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 12,873 shares of the biotechnology company's stock, valued at approximately $221,000.

A number of other hedge funds have also bought and sold shares of the company. National Bank of Canada FI acquired a new stake in shares of ADMA Biologics during the third quarter worth $35,000. GAMMA Investing LLC raised its stake in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new stake in ADMA Biologics during the fourth quarter worth about $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics in the fourth quarter worth about $51,000. Finally, AlphaQuest LLC acquired a new position in ADMA Biologics in the fourth quarter valued at approximately $84,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

ADMA Biologics stock traded up $0.39 during midday trading on Monday, reaching $18.40. 4,807,605 shares of the stock traded hands, compared to its average volume of 3,541,721. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of 65.71 and a beta of 0.53. The firm has a fifty day moving average price of $17.49 and a two-hundred day moving average price of $18.18.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.